Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 psychiatric EHR for ketamine/psychedelic/TMS treatment practices; $55.2M total ($40M DFJ/General Catalyst/Tiger Series B May 2022) competing with Valant for emerging mental health treatment specialty EHR.
Osmind is a San Francisco-based psychiatry and mental health EHR (electronic health record) platform — backed by Y Combinator (W20) with $55.2 million in total funding including a $40 million Series B in May 2022 led by DFJ Growth with General Catalyst, Future Ventures, Tiger Global, Susa Ventures, Lachy Groom, and Pear VC — providing psychiatric practices with research-grade EHR technology specialized for emerging mental health treatments including ketamine therapy, psychedelic-assisted psychotherapy (psilocybin, MDMA), transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT). Founded in 2020, Osmind captures clinical data during novel psychiatric interventions in structured formats that enable both optimized patient care workflows and real-world evidence research — serving the growing segment of psychiatric practices offering treatment-resistant depression interventions.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.